To include your compound in the COVID-19 Resource Center, submit it here.

Erbitux cetuximab: Additional Phase III data

Additional data from the open-label, U.K. and Irish Phase III COIN trial in 1,630 patients with previously untreated mCRC showed that Erbitux

Read the full 227 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE